BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia
Estupiñán, H Yesid HY; Wang, Qing Q; Berglöf, Anna A; Schaafsma, Gerard C P GCP; Shi, Yuye Y; Zhou, Litao L; Mohammad, Dara K DK; Yu, Liang L; Vihinen, Mauno M; Zain, Rula R; Smith, C I Edvard CIE